The copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction regiospecifically produces 1,4-disubstituted-1,2,3-triazole molecules. This heterocycle formation chemistry has high tolerance to reaction conditions and substrate structures. Therefore, it has been practiced not only within, but also far beyond the area of heterocyclic chemistry. Herein, the mechanistic understanding of CuAAC is summarized, with a particular emphasis on the significance of copper/azide interactions. Our analysis concludes that the formation of the azide/copper(I) acetylide complex in the early stage of the reaction dictates the reaction rate. The subsequent triazole ring-formation step is fast and consequently possibly kinetically invisible. Therefore, structures of substrates and copper catalysts, as well as other reaction variables that are conducive to the formation of the copper/alkyne/azide ternary complex predisposed for cycloaddition would result in highly efficient CuAAC reactions. Specifically, terminal alkynes with relatively low pKa values and an inclination to engage in π-backbonding with copper(I), azides with ancillary copper-binding ligands (aka chelating azides), and copper catalysts that resist aggregation, balance redox activity with Lewis acidity, and allow for dinuclear cooperative catalysis are favored in CuAAC reactions. Brief discussions on the mechanistic aspects of internal alkyne-involved CuAAC reactions are also included, based on the relatively limited data that are available at this point.

This paper describes the implementation of a biochemical and biophysical screening strategy to identify and optimize small molecule Akt1 inhibitors that act through a mechanism distinct from that observed for kinase domain ATP-competitive inhibitors. With the aid of an unphosphorylated Akt1 cocrystal structure of 12j solved at 2.25 Å, it was possible to confirm that as a consequence of binding these novel inhibitors, the ATP binding cleft contained a number of hydrophobic residues that occlude ATP binding as expected. These Akt inhibitors potently inhibit intracellular Akt activation and its downstream target (PRAS40) in vitro. In vivo pharmacodynamic and pharmacokinetic studies with two examples, 12e and 12j, showed the series to be similarly effective at inhibiting the activation of Akt and an additional downstream effector (p70S6) following oral dosing in mice.

Herein, we detail the optimization of the mGlu negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu NAM scaffold. This new chemotype not only affords potent and selective mGlu inhibition, as exemplified by VU6001966 (mGlu IC = 78 nM, mGlu IC > 30 μM), but also excellent central nervous system (CNS) penetration ( = 1.9, = 0.78), a feature devoid in all previously disclosed mGlu NAMs (s ≈ 0.3, s ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu PET tracer development.

Copper(II) acetate under aerobic conditions catalyzes the formation of 5,5'-bis(1,2,3-triazole)s (5,5'-bistriazoles) from organic azides and terminal alkynes. This reaction is an oxidative extension of the widely used copper-catalyzed azide-alkyne "click" cycloaddition. The inclusion of potassium carbonate as an additive and methanol or ethanol as the solvent, and in many instances an atmosphere of dioxygen, promote the oxidative reaction to afford 5,5'-bistriazole at the expense of 5-protio-1,2,3-triazole (5-protiotriazole). If needed, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) as a ligand additive further accelerates the formation of 5,5'-bistriazoles. A convenient procedure to prepare TBTA is also reported to facilitate the adoption of this method for preparation of 5,5'-bistriazoles. Aromatic azide-derived 5,5'-bistriazoles possess rigid axially chiral structures with a broad distribution of dihedral angles, which may be explored as chiral ligands in enantioselective catalysis if decorated with proper functional groups.

An improved method has been developed for the preparation of 5-iodo-1,2,3-triazoles directly from organic azides and terminal alkynes by a reaction mediated by copper(I) and iodinating agents generated in situ. The major methodological advance of the current procedure is that it provides a high conversion and good iodo/proto selectivity with a broad range of substrates without using an excess of the alkyne, which was required in the previous method. The use of an accelerating ligand is essential to the success of reactions involving unreactive azides or alkynes. New mechanistic insights are provided, including the confirmation that a 1-iodoalkyne is formed as a key intermediate under the established conditions for the reaction.

Synthesis of 5-Iodo-1,2,3-triazoles from Organic Azides and Terminal Alkynes: Ligand Acceleration Effect, Substrate Scope, and Mechanistic Insights. -The improved method for the selective formation of 5-iodo-1,2,3-triazoles proceeds via an iodoalkyne intermediate under mild conditions. The use of an accelerating tris-triazolyl ligand is essential for the success of reactions involving unreactive azides or alkynes. -(BARSOUM, D. N.; BRASSARD, C. J.; DEEB, J. H. A.; OKASHAH, N.; SREENATH, K.; SIMMONS, J. T.; ZHU*, L.; Synthesis 45 (2013) 17, 2372-2386, http://dx.

Review: [71 refs.

This letter describes the further chemical optimization of VU0424238 (auglurant), an mGlu5 NAM clinical candidate that failed in non-human primate (NHP) 28 day toxicology due to accumulation of a species-specific aldehyde oxidase (AO) metabolite of the pyrimidine head group. Here, we excised the pyrimidine moiety, identified the minimum pharmacophore, and then developed a new series of saturated ether head groups that ablated any AO contribution to metabolism. Putative back-up compounds in this novel series provided increased sp3 character, uniform CYP450-mediated metabolism across species, good functional potency and high CNS penetration. Key to the optimization was a combination of matrix and iterative libraries that allowed rapid surveillance of multiple domains of the allosteric ligand.